18
Sep
Sep
Psychedelic compounds — most commonly psilocybin, LSD, and MDMA — are once again prominent in scientific, clinical, commercial, and policy discussions. Trials testing these compounds for depression, PTSD, and addiction have produced encouraging signals in some controlled settings, but the broader picture includes regulatory uncertainty, notable safety concerns, and uneven public understanding. Readers need clear, […]
